Novo Nordisk A/S (NONOF)

Market Cap	270.77B
Revenue (ttm)	49.58B +16.6%
Net Income	16.30B +9.6%
EPS	3.67 +10.1%
Shares Out	n/a
PE Ratio	16.61
Forward PE	17.72
Dividend	1.66 (2.63%)
Ex-Dividend Date	Mar 28, 2025

Volume	n/a
Average Volume	92,694
Open	58.77
Previous Close	58.77
Day's Range	58.21 - 58.77
52-Week Range	42.01 - 93.83
Beta	0.36
RSI	53.63
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 78,554
• Stock Exchange: OTCMKTS
• Ticker Symbol: NONOF

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK